Role of ribavirin in interferon-free therapy for the treatment of hepatitis C virus

Real‐world use of elbasvir‐grazoprevir in patients with chronic hepatitis C: retrospective analyses from the TRIO network

“…In this analysis of HCV treatment in clinical practice settings, response rates to elbasvir-grazoprevir with or without ribavirin were F I G U R E 1 Assessment of variable association with per protocol (left) and intent-to-treat (right) SVR12. Variables with significant association are indicated in red profiles than interferon and ribavirin regimens, 17 and in our study, only 2 patients discontinued because of adverse events. Yet completion of treatment and follow-up visits remains problematic for some patients, as evidenced by this study and other analyses.…”

“…In the earlier era of hepatitis C treatment with interferon and ribavirin, discontinuation rates were high in part because of poor tolerability associated with both drugs. All DAA regimens have more favourable side effect profiles than interferon and ribavirin regimens, and in our study, only 2 patients discontinued because of adverse events. Yet completion of treatment and follow‐up visits remains problematic for some patients, as evidenced by this study and other analyses.…”

Therapeutic effects of interferons in human viral infections

“…Attempts have been made in the form of monotherapy for six months, which showed a response rate of 10.0% to 15.0%, representing a ratio that has risen to the range of 20.0% to 25.0% with administration for 12 to 18 months. Nevertheless, the combination of PEGylated IFNα-2b and ribavirin is currently the first-line therapy for patients with chronic hepatitis C. The combination has been shown to reduce the morbidity and mortality rates of patients receiving this treatment (Morillas et al, 2017;Ramos-Bellos and Ramos-Niembrob, 2008).…”